Patient Experiences and Preferences Regarding Medication Cost Discussions Among Heart Failure Patients in Singapore: A Qualitative Survey

被引：0
作者：
Shen, Qianyu [1 ]
Chua, Dennis Chin Wee [2 ]
Chan, Po Fun [3 ]
Chan, Sean Wei Jun [1 ]
Wee, Hwee-Lin [1 ]
机构：
[1] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, 12 Science Dr 2, Singapore 117549, Singapore
[2] Ng Teng Fong Gen Hosp, Dept Pharm, Singapore, Singapore
[3] Ng Teng Fong Gen Hosp, Dept Cardiol, Singapore, Singapore
来源：
PATIENT PREFERENCE AND ADHERENCE | 2025年 / 19卷
关键词：
cost discussion; decision making; patient experience; patient preference; heart failure; FINANCIAL TOXICITY; COMMUNICATION; CANCER; CARE;
D O I：
10.2147/PPA.S502235
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Purpose: Cost of novel medications has increased worldwide, causing financial toxicity to heart failure patients. Patients can discuss medication costs with clinicians to manage financial burden, but such discussion can be uncommon. This study seeked to investigate the experiences and preferences of heart failure patients in Singapore regarding medication cost discussions to develop effective strategies to encourage such conversations. Patients and Methods: Participants were recruited from a hospital outpatient heart failure clinic in 2022 to participate in a qualitative survey containing open-ended questions. Inclusion criteria were patients aged 21 years and above, diagnosed with heart failure, and capable of comprehending English. There were no exclusion criteria. Conventional content analysis was performed on collected responses. Results: Among forty-eight heart failure patients (median age: 63.5 years, 43.8% male, 72.9% Chinese) who participated, most (93.8%) wanted to discuss medication costs with clinicians for reasons such as concern over affordability, taking ownership of health, making informed decisions, minimizing inconvenience, and obtaining tailored cost information. Affordability of medications was a concern for patients but only 8.3% of patients actually had regular cost discussions with clinicians in the past year. Patients mentioned a lack of initiative from the clinicians, limited cost awareness, and time constraints as reasons why cost conversations did not happen. Conclusion: Outpatient heart failure patients in Singapore desire to discuss medication costs with clinicians but few participants reported having such conversations. Barriers hindering cost discussions have to be addressed to ensure patients make an informed medication decision with minimal financial burden.
引用
收藏
页码：407 / 418
页数：12
相关论文
共 48 条
  • [1] Vincent Rajkumar S., The high cost of prescription drugs: Causes and solutions, Blood Cancer J, 10, 6, (2020)
  • [2] Balon R., The inexplicable rise of medication prices, Ann Clin Psychiatry, 30, 3, pp. 165-166, (2018)
  • [3] Darien G, Wilson C, Balch A, Angove R., Talking about the cost of care: A critical component of shared decision making patient and provider perspectives, J National Med Assoc, 112, 5, pp. 503-506, (2020)
  • [4] De Souza JA, Yap BJ, Hlubocky FJ, Et al., The development of a financial toxicity patient-reported outcome in cancer: The COST measure, Cancer, 120, 20, pp. 3245-3253, (2014)
  • [5] Zafar SY, Peppercorn JM, Schrag D, Et al., The financial toxicity of cancer treatment: A pilot study assessing out-of-pocket expenses and the insured cancer patient’s experience, oncologist, 18, 4, (2013)
  • [6] Bestvina CM, Zullig LL, Rushing C, Et al., Patient-oncologist cost communication, financial distress, and medication adherence, J Oncol Pract, 10, 3, pp. 162-167, (2014)
  • [7] Neugut AI, Subar M, Wilde ET, Et al., Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer, J Clin Oncol, 29, 18, pp. 2534-2542, (2011)
  • [8] Piette JD, Heisler M, Wagner TH., Cost-related medication underuse: Do patients with chronic illnesses tell their doctors?, Archives of Internal Medicine, 164, 16, pp. 1749-1755, (2004)
  • [9] McDonagh TA, Metra M, Adamo M, Et al., ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure, Eur Heart J, 42, 36, pp. 3599-3726, (2021)
  • [10] Heidenreich PA, Bozkurt B, Aguilar D, Et al., AHA/ACC/HFSA guideline for the management of heart failure: A report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines, Circulation, 145, 18, pp. e895-e1032, (2022)
12345